

COPY

#6

PTO/SB/08 (2-92)
Sheet 1 of 3

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312007400

Application Number 09/724,822

Applicant

Matthew D. LINNIK and Patricia A. McNEELY

Filing Date November 28, 2000

Group Art Unit 1646

Mailing Date September 18, 2001

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CQ	1.	11/10/1992	5,162,515	Conrad et al.			
	2.	12/07/1993	5,268,454	Barstad et al.			
	3.	01/04/1994	5,276,013	Conrad et al.			
	4.	12/06/1994	5,370,871	Dintzis et al.			
	5.	02/21/1995	5,391,785	Jones et al.			
	6.	09/03/1996	5,552,391	Coutts et al.			
	7.	02/25/1997	5,606,047	Coutts et al.			
	8.	05/27/1997	5,633,395	Coutts et al.			
	9.	03/10/1998	5,726,329	Jones et al.			
	10.	07/28/1998	5,786,512	Jones et al.			
	11.	02/23/1999	5,874,409	Victoria et al.			
	12.	02/08/2000	6,022,544	Dintzis et al.			
	13.	05/09/2000	6,060,056	Coutts et al.			
	14.	03/27/2001	6,207,160 B1	Victoria et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CQ	15.	12/19/1996	WO 96/40197	PCT			
	16.	12/11/1997	WO 97/46251	PCT			
	17.	12/16/1999	WO 99/64595	PCT			
	18.	06/15/2000	WO 00/33887	PCT			
	19.	06/15/2000	WO 00/34231	PCT			
	20.	06/15/2000	WO 00/34296	PCT			
	21.	12/14/2000	WO 00/75105	PCT			

EXAMINER:

DATE CONSIDERED: 8/7/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. McNEELY	
	Filing Date November 28, 2000	Group Art Unit 1646
	Mailing Date September 18, 2001	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
ce	20.	Bootsma, H. et al. (1995). "Prevention of Relapses in Systematic Lupus Erythematosus", <i>Lancet</i> , 345:1595-1599.
	21.	Borel, Y. et al. (1990) "A Novel Technique to Link Either Proteins or Peptides to Gammaglobulin to Construct Tolerogens" <i>J. Immunol. Methods</i> 126:159-168.
	22.	Borel, Y. et al. (1995) "Food Allergens Transformed into Tolerogens" <i>Int. Arch. Allergy Immunol.</i> 107:264-267.
	23.	Borel, Y. et al. (1996) "Parenteral and Oral Administration of Tolerogens: Protein-IgG Conjugates" <i>Ann. N.Y. Acad. Sci.</i> 778:80-87.
	24.	Borg, E. J. et al. (1990). "Measurement of Increases in Anti-Double-Stranded DNA Antibody Levels as a Predictor of Disease Exacerbation in Systemic Lupus Erythematosus", <i>Arthritis Rheumatism</i> . 33:634-643.
	25.	Coutts, S. M. et al. (1996). "Pharmacological Intervention in Antibody Mediated Disease", <i>Lupus</i> 5:158-159.
	26.	Dintzis, R. Z. et al. (1983). "Studies on the Immunogenicity and Tolerogenicity of T-Independent Antigens", <i>The Journal of Immunology</i> 13(5):2196-2203.
	27.	Dintzis, R. Z. et al. (1989). "The Immunogenicity of Soluble Haptenated Polymers is Determined by Molecular Mass and Hapten Valence", <i>The Journal of Immunology</i> 143:1239-1244.
	28.	Dumas, V. et al. (1995). "Induction of Tolerance by Administration of Hapten-Immunoglobulin Conjugates is Associated with Decreased IL-2 and IL-4 Production", <i>Arch. Dermatol. Res.</i> , 287:123-128.
	29.	Foster, M. H. et al. (1993). "Biology of Disease Nephritogenic Autoantibodies in Systematic Lupus Erythematosus: Immunochemical Properties, Mechanisms of Immune Deposition, and Genetic Origins", <i>Laboratory Investigation</i> , 69(5):494-507.
	30.	Jones, D. et al. (1994). "Conjugates of Double -Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: a Model for Treating Systematic Lupus Erythematosus", <i>Bioconjugate Chemistry</i> 5:390-399.
	31.	Jones, D. et al. (1995). "Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetakis-Oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis", <i>J. Med. Chem.</i> 38:2138-2144.
✓	32.	Morimoto, C. et al. (1982). "A Defect of Immunoregulatory T Cell Subsets in Systematic Lupus Erythematosus Patients Demonstrated with Anti-2H4 Antibody", <i>The Journal of Immunology</i> 139:1960-1965.

EXAMINER:


DATE CONSIDERED:


8/7/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 252312007400	Application Number 09/724,822
	Applicant Matthew D. LINNIK and Patricia A. McNEELY	
	Filing Date November 28, 2000	Group Art Unit 1646
	Mailing Date September 18, 2001	

CA	33.	Plunkett, M. L. et al. (1995). "LJP 394: A Novel Clinical Candidate for the Treatment of Lupus Nephritis", <i>Lupus</i> 4:S99.
	34.	Seleznick, M. J. et al. (1991). "Variables Associated with Decreased Survival in Systematic Lupus Erythematosus", <i>Seminars in Arthritis and Rheumatism</i> 21:73-80.
	35.	Sem, D. S. et al. (1999). "Antibody Affinities and Relative Titers in Polyclonal Population: Surface Plasmon Resonance Analysis of Anti-DNA Antibodies", <i>Archives of Biochemistry and Biophysics</i> 1:372(1):62-68.
↓	36.	Weisman, M. H. et al. (1997). "Reduction in Circulating dsDNA Antibody Titer after Administration of LJP 394", <i>The Journal of Rheumatology</i> 24:314-318.

EXAMINER: 	DATE CONSIDERED: 8/7/03
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-149

Docket Number 252312007400

Application Number 09/724,822

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Matthew D. LINNIK and Patricia A. McNEELEY

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date April 17, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
CQ	1.	06/30/1992	5,126,131	Dintzis et al.			
	2.	11/28/1995	5,470,570	Taylor et al.			
	3.	01/30/1996	5,487,890	Taylor et al.			
	4.	03/09/1999	5,879,679	Taylor et al.			
	5.	06/04/2002	6,399,578	Jack et al.			
	6.	10/01/2002	6,458,953	Jones			

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
CQ	7.	08/20/1992	WO 92/13558	WIPO			
	8.	02/04/1993	WO 93/02093	WIPO			
	9.	03/16/1995	WO 95/07073	WIPO			
	10.	06/28/2001	WO 01/45669	WIPO			
	11.	11/01/2001	WO 01/80883	WIPO			
	12.	06/13/2002	WO 02/46208	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)


Examiner Initials	Ref. No.	Title
CQ	13.	Alarcón-Segovia, D. et al. (2003). "LJP 394 for the Prevention of Renal Flare in Patients with Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 48(2):442-454.
	14.	Craig, M. L. et al. (2000). "Clearance of Anti-Double-Stranded DNA Antibodies," <i>Arthritis & Rheumatism</i> 43(10):2265-2275.
	15.	Ferguson, P. J. et al. (1995). "Antigen-Based Heteropolymers," <i>Arthritis & Rheumatism</i> 38(2):190-200.

EXAMINER:

DATE CONSIDERED:

8/7/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 252312007400

Application Number 09/724,822

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Matthew D. LINNIK and Patricia A. McNEELEY

Filing Date November 28, 2000

Group Art Unit 1636

Mailing Date April 17, 2003

CQ	16.	Taylor, R. P and Ferguson, P. J. (1995). "Immune Complexes (IC) Bound to Erythrocyte (E) CR1 via Anti-CR1 Mabs are Cleared Simultaneously with Loss of E CR1 in a Concerted Reaction in a Rhesus Monkey Model," Abstract 1000, <i>Arthritis and Rheumatism</i> 38(6):S320.
	17.	Taylor, R. P. and Ferguson, P. J. (1995). "Primate Erythrocyte (E) Complement Receptor (CR1) as an Anchor Site for Bispecific-Based Therapies to Clear Pathogens or Autoantibodies Safely from the Circulation," <i>Journal of Hematotherapy</i> 4:357-362.
	18.	Wiseman, A. (October 22, 2002). "La Jolla Pharmaceutical to Complete Enrollment of Phase III Lupus Clinical Trial." Press Release, two pages total.
	19.	Wiseman, A. (February 18, 2003). "La Jolla Pharmaceutical Announces Results of Phase III Trial of Riquent™." Press Release, six pages total.

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

8/7/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.